Share Email Print
cover

Proceedings Paper

Acne phototherapy using UV-free high-intensity narrow-band blue light: a three-center clinical study
Author(s): Alan R. Shalita; Yoram Harth; Monica Elman; Michael Slatkine; Gerry Talpalariu; Yitzhak Rosenberg; Avner Korman; Arieh Klein
Format Member Price Non-Member Price
PDF $17.00 $21.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Propionibacterium. acnes is a Gram positive, microaerophilic bacterium which takes a part in the pathogenesis of inflammatory acne. P. acnes is capable to produce high amounts endogenic porphyrins with no need of any trigger molecules. Light in the violet-blue range (407-420 nm) has been shown to exhibit a phototoxic effect on Propionibacterium acnes when irradiated in vitro. The purpose of our study was to test the clinical effects of a high intensity narrowband blue light source on papulo pustular acne. A total of 35 patients in 3 centers were treated twice a week with a high intensity metal halide lamp illuminating the entire face (20x20 cm2) or the back with visible light in the 407-420 nm range at an intensity of 90 mW/cm2 (CureLight Ltd.) for a total of 4 weeks. UV is totally cut off. In each treatment the patient was exposed to light for 8-15 minutes. After 8 treatments, 80% of the patients with mild to moderate papulo-pustular acne showed significant improvement at reducing the numbers of non- inflammatory, inflammatory and total facial lesions. Inflammatory lesion count decrease by a mean of 68%. No side effects to the treatment were noticed. In conclusion, full face or back illumination with the high intensity pure blue light we used exhibits a rapid significant decrease in acne lesions counts in 8 biweekly treatments.

Paper Details

Date Published: 21 May 2001
PDF: 13 pages
Proc. SPIE 4244, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI, (21 May 2001); doi: 10.1117/12.427830
Show Author Affiliations
Alan R. Shalita, SUNY/Downstate Medical Ctr. at Brooklyn (United States)
Yoram Harth, CureLight Ltd. (Israel)
Monica Elman, Beit-Harofim (Israel)
Michael Slatkine, ESC/Sharplan Inc. (Israel)
Gerry Talpalariu, ESC/Sharplan Inc. (Israel)
Yitzhak Rosenberg, ESC/Sharplan Inc. (United States)
Avner Korman, CureLight Ltd. (United States)
Arieh Klein, ESC/Sharplan Inc. (Israel)


Published in SPIE Proceedings Vol. 4244:
Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI
Lawrence S. Bass M.D.; David S. Robinson M.D.; Eugene A. Trowers M.D.; Kenton W. Gregory M.D.; Lou Reinisch; Kenneth Eugene Bartels D.V.M.; R. Rox Anderson M.D.; Reza S. Malek M.D.; Kenneth Eugene Bartels D.V.M.; Lloyd P. Tate V.D.M.; Abraham Katzir; C. Gaelyn Garrett M.D.; Timothy A. Woodward M.D.; Hans-Dieter Reidenbach; George M. Peavy D.V.M.; Lawrence S. Bass M.D.; C. Gaelyn Garrett M.D.; Michael D. Lucroy D.V.M.; Kenton W. Gregory M.D.; Abraham Katzir; Nikiforos Kollias; Michael D. Lucroy D.V.M.; Reza S. Malek M.D.; J. Stuart Nelson M.D.; George M. Peavy D.V.M.; Hans-Dieter Reidenbach; Lou Reinisch; David S. Robinson M.D.; Lloyd P. Tate V.D.M.; Eugene A. Trowers M.D.; Timothy A. Woodward M.D., Editor(s)

© SPIE. Terms of Use
Back to Top